🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 15 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
10/11/2015 26,80 30,48 26,42 29,30 +6,70% 15,15% 1.249.100
09/11/2015 28,07 28,67 27,28 27,46 -2,24% 4,95% 561.300
06/11/2015 27,02 28,49 26,35 28,09 +4,00% 7,92% 852.700
05/11/2015 27,49 27,67 26,03 27,01 -2,39% 5,97% 601.400
04/11/2015 27,82 28,48 26,43 27,67 -1,32% 7,37% 849.100
03/11/2015 27,44 28,33 25,70 28,04 +1,45% 9,58% 1.185.600
02/11/2015 25,18 27,71 24,87 27,64 +11,14% 11,26% 1.047.500
30/10/2015 23,75 25,45 23,40 24,87 +3,80% 8,63% 1.028.500
29/10/2015 25,22 26,20 23,70 23,96 -5,00% 9,91% 930.200
28/10/2015 23,42 25,25 22,67 25,22 +6,68% 11,02% 1.212.100
27/10/2015 24,26 25,14 23,24 23,64 -2,43% 7,83% 870.400
26/10/2015 25,22 25,67 24,08 24,23 -5,35% 6,30% 542.500
23/10/2015 24,91 26,40 24,71 25,60 +2,44% 6,78% 840.800
22/10/2015 25,28 26,00 24,10 24,99 -1,96% 7,52% 904.000
21/10/2015 27,50 27,67 24,35 25,49 -5,07% 12,07% 1.294.500
20/10/2015 30,04 30,72 26,80 26,85 -9,26% 13,05% 1.472.100
19/10/2015 34,25 35,74 28,23 29,59 -16,06% 21,92% 2.745.600
16/10/2015 34,01 35,75 31,26 35,25 +11,06% 13,20% 7.155.000
15/10/2015 30,11 31,86 29,42 31,74 +5,87% 8,10% 2.835.000
14/10/2015 29,40 30,85 26,90 29,98 +2,60% 13,44% 1.275.700
13/10/2015 31,14 32,05 28,88 29,22 -7,03% 10,18% 671.800
12/10/2015 35,00 35,49 31,03 31,43 -8,18% 12,74% 1.153.900
09/10/2015 31,74 35,76 31,00 34,23 +7,14% 15,00% 933.000
08/10/2015 30,98 33,10 29,52 31,95 +1,46% 11,56% 1.040.300
07/10/2015 29,18 33,82 28,67 31,49 +8,40% 17,63% 1.180.300
06/10/2015 29,26 29,74 26,70 29,05 -1,39% 10,39% 794.700
05/10/2015 30,88 31,75 27,01 29,46 -1,87% 15,35% 833.500
02/10/2015 26,57 30,08 26,51 30,02 +10,45% 13,44% 866.500
01/10/2015 26,64 27,77 24,97 27,18 +1,80% 10,52% 690.200
30/09/2015 26,00 28,34 24,75 26,70 +6,33% 13,81% 1.030.200